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 Background: Multiple sclerosis is a human autoimmunological disease that causes neurodegeneration. One of the potential 
ways to stop its development is induction of oral tolerance, whose effect lies in decreasing immune response 
to the fed antigen. It was shown in animal models that administration of specific epitopes of the three main 
myelin proteins – myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), and proteolipid pro-
tein (PLP) – results in induction of oral tolerance and suppression of disease symptoms. Use of bacterial cells 
to produce and deliver antigens to gut mucosa seems to be an attractive method for oral tolerance induction 
in treatment of diseases with autoimmune background.
 Material/Methods: Synthetic genes of MOG35-55, MBP85-97, and PLP139-151 myelin epitopes were generated and cloned in 
Lactococcus lactis under a CcpA-regulated promoter. The tolerogenic effect of bacterial preparations was test-
ed on experimental autoimmune encephalomyelitis, which is the animal model of MS. EAE was induced in rats 
by intradermal injection of guinea pig spinal cord homogenate into hind paws.
 Results: Rats were administered preparations containing whole-cell lysates of L. lactis producing myelin antigens using 
different feeding schemes. Our study demonstrates that 20-fold, but not 4-fold, intragastric administration of 
autoantigen-expressing L. lactis cells under specific conditions reduces the clinical symptoms of EAE in rats.
 Conclusions: The present study evaluated the use of myelin antigens produced in L. lactis in inhibiting the onset of experi-
mental autoimmune encephalomyelitis in rats. Obtained results indicate that application of such recombinant 
cells can be an attractive method of oral tolerance induction.
 MeSH Keywords: Encephalomyelitis, Autoimmune • Lactococcus lactis • Myelin Proteins
 Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/892764
Authors’ Contribution: 
Study Design A
 Data Collection B
 Statistical Analysis C
Data Interpretation D
 Manuscript Preparation E
 Literature Search F
Funds Collection G
1 Department of Experimental and Clinical Physiology, Laboratory of Centre for 
Preclinical Research, Medical University of Warsaw, Warsaw, Poland
2 Department of Neuropeptides, Mossakowski Medical Research Center, Polish 
Academy of Sciences, Warsaw, Poland
3 Department of Microbial Biochemistry, Institute of Biochemistry and Biophysics, 
Polish Academy of Sciences, Warsaw, Poland
e-ISSN 1643-3750
© Med Sci Monit, 2015; 21: 1587-1597
DOI: 10.12659/MSM.892764
1587
Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System]  
[ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica]  
[Chemical Abstracts/CAS] [Index Copernicus]
This work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivs 3.0 Unported License
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Background
Multiple sclerosis (MS) is an autoimmune disease that has a 
serious impact on physical abilities of the patient. It is pos-
tulated to involve cell-mediated and humoral responses di-
rected against myelin proteins, including myelin basic protein 
(MBP), proteolipid protein (PLP), myelin-associated glycopro-
tein (MAG), and myelin oligodendrocyte glycoprotein (MOG) 
[1–6]. This immunoactivity causes inflammation that leads to 
demyelination and axonal loss in the central nervous system 
(CNS) and results in slowing or even breaking neurotransmis-
sion [7]. The etiology of MS remains unknown and the com-
mercially available medicines do not prevent disease devel-
opment [8,9]. Currently, the most effective MS treatments are 
based on general immunosuppression or immunomodulation, 
which may lead to a number of adverse effects (e.g., common 
bacterial and viral infections, mood swings, high blood pres-
sure, weight gain), including severe adverse effects such as 
progressive multifocal leukoencephalopathy. Data show that 
after 6 years of treatment, the disability of people with multiple 
sclerosis is the same as without drug therapy (Kwiatkowska-
Patzer, personal communication).
An alternative treatment relies on induction of a state termed 
oral tolerance. Most simply, oral tolerance can be defined as the 
decrease of response to a previously fed antigen. It is a com-
mon physiological state preventing the formation of systemic 
immune responses to proteins ingested daily [10]. Preclinical 
trials show that on the same basis, oral administration of au-
toantigens induces a response suppressing experimental au-
toimmune diseases [11]. Studies using the experimental al-
lergic encephalomyelitis (EAE), an animal model of MS, have 
shown that intradermal injection of myelin antigens such as 
MBP, MOG or PLP proteins with Freund’s adjuvant leads to de-
velopment of acute paralysis [12–14]. However, oral adminis-
tration of a myelin antigen or antigens before injection inhib-
its paralysis signs and immune cells infiltration as shown in 
histopathological studies [15,16]. Moreover, feeding with my-
elin antigens after the onset of EAE was determined to reduce 
disease development and facilitate remission [17]. Also, our 
own previous studies have demonstrated that intragastric ad-
ministration of pig spinal cord hydrolysate, containing short 
peptide fragments of myelin proteins, induces oral tolerance 
in Wistar and Lewis rats with EAE [18–20]. Results indicated 
that the mixture of neuropeptides in the spinal cord hydroly-
sate given orally diminished immunological response to my-
elin antigens [21]. This initiated further studies on develop-
ing novel means of delivering myelin peptides to gut mucosa 
in combination with proficient production of selected autoan-
tigens in bacterial cells.
Various studies show that peptides MOG35-55, MBP85-97, 
and PLP139-151 are epitopes that play a role in inhibiting 
autoantigen responses, both in MS patients and animals with 
EAE [17,22,23]. Therefore, they are generally considered as good 
antigens for oral tolerance induction. All of the above obser-
vations encourage continuing studies on the development of 
autoimmune disease treatment.
One of the strategies of delivering antigens to mucosal sur-
faces is the use of bacterial cells as carriers. Commonly, anti-
gen delivery systems were based on attenuated pathogenic 
microorganisms or viruses such as Salmonella typhi or polio-
virus [24,25]. An interesting alternative that has been gain-
ing much interest in the last decades is the potential use of 
non-pathogenic bacteria as live oral vaccines. In this work we 
developed a system for production of selected epitopes from 
natural myelin proteins in a lactic acid bacterium (LAB). LAB 
are gram-positive, food-grade bacteria with various applica-
tions in food production and dairy fermentation [26,27]. Due to 
their recognized, non-pathogenic nature, LAB are of substan-
tial interest for implementation in various research domains, 
including vaccine development, where they are considered as 
attractive antigen delivery vectors, and a good alternative to 
commonly used attenuated pathogens [28,29]. Lactococcus 
lactis is a model LAB that has been shown to efficiently pro-
duce heterologous proteins of different origin (e.g., viral, bac-
terial, mammalian) [30–33]. Numerous studies demonstrated 
that oral delivery of allergen- or autoantigen-expressing L. lac-
tis cells can be a cost-effective and innovative means of induc-
ing tolerance [34–36]. Among other evidence, it was shown 
that delivery of the ovalbumin-expressing L. lactis strain to the 
gut mucosal surface suppresses both systemic and local OVA-
specific T-cell response [36].
These reports induced us to employ L. lactis as a host organ-
ism to produce myelin epitopes MOG35-55, MBP85-97, and 
PLP139-151 and deliver them to gut mucosa. For this, we gen-
erated synthetic genes of these peptide fragments and ex-
pressed them using the promoter region of the L. lactis ptcB 
gene (PptcB) inserted into the pIL253 vector. Previous studies 
have shown that the ptcB gene in L. lactis is engaged in sug-
ar catabolism, and its promoter (PptcB) is regulated by CcpA, 
the catabolite control protein A [37]. The strength of PptcB 
was shown to vary depending on the sugar source in the me-
dium. The highest promoter activation was determined to oc-
cur in the presence of cellobiose [37, Aleksandrzak-Piekarczyk 
– unpublished data]. Animal trials showed that oral adminis-
tration of recombinant L. lactis cells encoding myelin epitopes 
can at certain doses inhibit progression of experimental auto-
immune encephalomyelitis induced in rats. A scheme of anti-
gen administration was also examined.
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Material and Methods
Bacterial strains and plasmids
Strains and plasmids used in this work are listed in Table 1. 
Plasmid vector pIL253:PptcB, carrying the promoter region of 
L. lactis ptcB gene, was used in cloning procedures. L. lactis cells 
were grown at 30°C in M17 liquid medium supplemented with 
0.5% cellobiose or on M17 solid medium containing 0.5% glu-
cose [38]. Solid plate media contained 1.5% agar. When nec-
essary the growth medium was supplemented with erythro-
mycin at 5 µg/ml (for plasmid-carrying L. lactis derivatives).
DNA manipulations, transformation and sequencing
Standard DNA manipulations and cloning procedures were per-
formed as described previously [39]. Transformation of L. lac-
tis cells via electroporation was done as described elsewhere 
[40,41]. Digestions with restriction enzymes (Fermentas) were 
done according to the manufacturer’s instructions. DNA se-
quencing was done using a Big Dye sequencing kit. Sequences 
were analyzed with the BLAST program [42].
Cloning of MOG35-55, MBP85-97 and PLP139-151 
synthetic gene fragments in L. lactis
Oligonucleotides used in this study are listed in Table 2. Two ‘LONG’ 
complementary oligonucleotides served as a template for ampli-
fication of neuropeptide-encoding sequences. Oligonucleotides 
were designed in accordance with the codon usage of L. lactis spe-
cies to give the nucleotide sequence corresponding to the ami-
no acid sequence of a given peptide fragment that is the most 
optimal for these bacteria. PCR reaction was performed with the 
Thermocycler apparatus using ExTaq DNA polymerase (TaKaRa) 
and, specific for each peptide, ‘SHORT’ primer pairs complemen-
tary to the 5’ ends of ‘LONG’ primers (Table 2). The resulting PCR 
products were then digested with PstI and SalI restriction en-
zymes (Fermentas) and ligated into the pIL253:PptcB vector cut 
with the same pair of enzymes. Ligated molecules were electro-
porated into L. lactis cells. Transformants were selected on M17 
medium (Oxoid) supplemented with 1.5% agar, 0.5% glucose, and 
5 µg/ml erythromycin to isolate cells carrying either the empty 
[pIL253:PptcB] or recombinant vectors. Colonies carrying single 
neuropeptide-containing plasmids were analyzed by ‘colony PCR’ 
technique using specific primers: ptcBfor/pILrev (Table 2). From 
confirmed proper recombinant cells, plasmid DNA was isolated 
using the Plasmid Mini Kit (A&A Biotechnology) and subjected 
to restriction analysis with HindIII enzyme (Fermentas). Obtained 
digestion pattern was compared to the pattern generated using 
the CloneManager 9 (Sci-Ed Software) program. Finally, nucleo-
tide sequences of the cloned DNA fragments were examined for 
conformity with the nucleotide sequences of the synthetic my-
elin genes by DNA sequencing technique.
Transcriptional analysis of MOG35-55, MBP85-97 and 
PLP139-151 synthetic gene expression in L. lactis
Expression of the cloned neuropeptide synthetic gene sequenc-
es was analyzed by RT-PCR using SuperScriptIII (Invitrogen). 
Total RNA was isolated from recombinant L. lactis cells carry-
ing individual neuropeptide synthetic genes using High Pure 
RNA isolation kit (Roche). To eliminate residual DNA, total RNA 
was additionally digested with DNase I (Sigma) and subject-
ed to RT-PCR reaction using a reverse ‘SHORT’ primer specific 
for each neuropeptide-encoding gene (Table 2).
Preparation of recombinant L. lactis whole-cell extracts
Recombinant lactococci were prepared for intragastric admin-
istration as follows. After o/n incubation at 30°C, the bacterial 
culture was harvested (8 000 g, 10 min., 4°C) and washed once 
with 0.9% NaCl. Then, cells were suspended in 0.9% NaCl and 
disrupted 3 times for 1 min using the MiniBeadbeater (BioSpec 
Products) and 106-µm glass beads (Sigma). To determine the 
amount of myelin peptides that should be delivered to the gut 
mucosa to evoke tolerance, adequate dilutions of cell lysates, 
corresponding to doses 101–108 CFU (Colony Forming Units) 
per 0.5 ml were made. Single doses were frozen in Eppendorf 
tubes in liquid nitrogen and stored at –20°C until needed.
Tolerance induction in rats with EAE using whole-cell 
extracts of L. lactis producing MOG35-55, MBP85-97 and 
PLP139-151
Female Lewis rats, 180–200 g, were fed intragastrically with 
a gauged pointed needle, four times during one week (every 
Strain Genotype Source
Lactococcus lactis IBB360 Natural isolate IBB PAS collection
Plasmid
pIL253:PptcB EryR, pIL253-derivative with ptcB gene promoter region IBB PAS collection
Table 1. Strains and plasmids.
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second day) or once a day for 20 consecutive days (from day 
–10 to +9). Preparations given to rats contained whole-cell 
L.  lactis lysates diluted in 0.5 ml PBS accordingly to give 101–108 
CFU per feeding. EAE was evoked a week after the last feed-
ing in respect to the 4-day scheme or on day 10 of the 20-day 
schedule. The day of immunization is marked as 0 DPI – day 
post immunization. To induce EAE, rats received intradermal 
injection of 50% guinea pig spinal cord homogenate in PBS, 
with Freund ’s adjuvant (1:1) and Mycobacterium tuberculosis 
(4 mg/ml), into hind paws (100 µl/paw). Rats were weighed 
every day and clinical symptoms were evaluated from the 
day they first occurred, using a 5-grade scale: 1 – limp tail, 2 
– hind leg weakness, 3 – hind leg paralysis and incontinence, 
4 – front and hind leg weakness or quadriplegia, 5 – death. 
On day 14 after immunization (DPI) animals were sacrificed.
Analysis of the therapeutic effect of L. lactis-produced 
peptide preparations on rats
The efficiency of bacterial preparations were assessed by calcu-
lating (i) mean score of clinical symptoms, and (ii) body mass, 
reflecting the overall condition of the animal. First clinical 
symptoms of EAE were observed at the 11 DPI. Peak of clini-
cal symptoms was noted between 11–14 DPI. The mean clini-
cal score was calculated for this time range. Body mass index 
was counted as the ratio of body mass at the end of experi-
ment [14 DPI] to body mass at the day of immunization [0 DPI]. 
Body mass at 0 DPI was considered as 1. Statistical evaluations 
were made using the Mann-Whitney test. A value of p less than 
0.05 was considered as statistically significant.
Experiments on animals have been carried out in accordance 
with the EU Directive 2010/63/EU for animal experiments 
and approved by the IV Local Ethics Committee for Animal 
Experiments in Warsaw (Act no. 66/2010 made on 08.10.2010).
Results
Designing of synthetic MOG35-55, MBP85-97 and 
PLP139-151 gene sequences
Synthetic genes encoding human-derived MOG35-55 (from 
MOG protein; gi: 56388814) MBP85-97 (from MBP protein; 
Neuropeptide Oligonucleotide Nucleotide sequence (forward/reverse)
Oligonucleotides („LONG”) used as DNA templates for amplification of synthetic neuropeptide genes
MOG35-55
FLONGMOG35
5’ GTATTTCTATGGAAGTTGGATGGTATCGTTCACC 
ATTTTCACGTGTTGTTCATTTATATCGTAATGG 3’
RLONGMOG35
5’ CCATTACGATATAAATGAACAACACGTGAAAAT 
GGTGAACGATACCATCCAACTTCCTAGAAATAC 3’
MBP85-97
FLONGMBP85 5’ GTATTTCTATGCCAGGATCACGTCCACATTTAATTCGTTTATTTTCACGT 3’
RLONGMBP85 5’ ACGTGAAAATAAACGAATTAAATGTGGACGTGATCCTGGCATAGAAATAC 3’
PLP139-151
FLONGPLP139 5’ GTATTTCTATGCATTCATTAGGAAAATGGTTAGGACATCCAGATAAATTT 3’
RLONGPLP139 5’ AAATTTATCTGGATGTCCTAACCATTTTCCTAATGAATGCATAGAAATAC 3’
Oligonucleotides (SHORT) used as primers for amplification of synthetic neuropeptide genes
Universal primer forward FSHORTUniv 5’ ACGCGTCGACAAGGAGTATTTCTATG 3’
MOG35-55 RSHORTMOG35 5’ AACTGCAGTTATTATTTTCCATTACGATA 3’
MBP85-97 RSHORTMBP85 5’ AACTGCAGTTATTAACGTGAAAATAAACG 3’
PLP139-151 RSHORTPLP139 5’ AACTGCAGTTATTAAAATTTATCTGG 3’
Oligonucleotides used as amplification primers complementary to pIL253:PptcB
pILfor 5’ TTAGAGTATACTTATTTGTCC 3’
pILrev 5’ GGGATAGTAATTCATTCCTGG 3’
ptcBfor 5’ GCGATTAATGTCGCCTAAAGGTTGC 3’
ptcBrev 5’ AATCCCGGCGTTTTATAATTTAACGTTC 3’
Table 2. Oligonucleotide sequences used in study.
* RBS and spacer sequence marked in bold, sequences recognized by restriction enzymes are underlined.
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gi: 54038405AAH84713.1) and PLP139-151 (from PLP pro-
tein; gi: 13591880) epitopes were obtained by PCR method. 
For each peptide fragment, two complementary oligonucle-
otides (for/rev ‘LONG’) were used as template. To ensure effi-
cient gene expression associated with faster translation rates, 
all ‘LONG’ primers used in this study were designed taking into 
account optimal codon usage in L. lactis, obtained from the 
Codon Usage Database (www.kazusa.or.jp). Additionally, ‘LONG’ 
primers contained at their 5’ ends sequences specific for the 
Lactococcus lactis RBS (ribosome-binding site; AAGGAG) con-
sensus sequence recognized by the translation machinery and 
‘spacer’ sequence (TATTTCT) localized between the RBS region 
and the translation START codon. The forward ‘LONG’ primer 
used to amplify the PLP139-151-encoding gene was modified 
by introducing a sequence corresponding to the translation 
START codon (ATG), just before the original peptide sequence. 
Genes encoding myelin peptide fragments were generated by 
two oligonucleotides (for/rev ‘SHORT’) homologous to the ex-
tremities of the ‘LONG’ primers (Table 2).
Cloning of MOG35-55-, MBP85-97- and PLP139-151-
encoding genes in L. lactis
The generated synthetic genes were cloned separately into 
L. lactis-replicating pIL253:PptcB plasmid. Obtained recombinant 
vectors were introduced independently into electrocompetent 
cells by using an efficient transformation technique common-
ly used for L. lactis [40,41]. Clones containing synthetic genes 
were identified in the culture population by analyzing the ob-
tained transformants using ‘colony PCR’ technique for the pres-
ence of inserts corresponding in length to the expected DNA 
fragments (Figure 1). PCR performed directly on grown cells 
using specific primers, allowed isolating colonies specifically 
carrying recombinant vectors. Digestion patterns of obtained 
from recombinant plasmid DNA isolated from these colonies 
were in conformity with the predicted restriction pattern gen-
erated using bioinformatics program (Figure 2). Such result, in 
parallel with DNA sequencing, provided proof that these plas-
mids do not undergo any rearrangements and are stably main-
tained in L. lactis, suggesting at the same time that the encod-
ed myelin peptides are not toxic to the cells.
Figure 1.  Colony PCR on selected transformant clones. (A) pIL253:PptcB:MOG35-55 (8 clones tested), (B) pIL253:PptcB:MBP85-97 (3 
clones tested), (C) pIL253:PptcB:PLP139-151 (12 clones tested). Colony PCR carried out on transformant clones obtained 
after electroporation of L. lactis cells with recombinant constructs and selection of M17 solid medium supplemented with 
0.5% glucose and erythromycin at 5 µg/ml. Specific primers used (ptcBfor/pILrev) were homologous to the vector sequence 
flanking the potentially cloned fragment. Expected product size: ~550 bp (marked with red arrows), 1 kb DNA Ladder 
(Fermentas) used as DNA size reference marker.
Figure 2.  Control digestions of recombinant plasmid DNA using HindIII (Fermentas) enzyme. (A) pIL253:PptcB:MOG35-55, (B) 
pIL253:PptcB:MBP85-97, (C) pIL253:PptcB:PLP139-151. Expected DNA fragments after restriction analysis for correct 
constructs: 3897 bp, 845 bp (marked by red arrows), 1kb DNA ladder (M) 1kb DNA Ladder (Fermentas) used as DNA size 
reference marker.
A B C
M A B C
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Transcriptional studies on the expression of synthetic 
MOG35-55, MBP85-97 and PLP139-151 genes in L. lactis
To examine whether the cloned synthetic neuropeptide genes 
are properly expressed in L. lactis, transcriptional studies us-
ing RT-PCR have been carried out. Total RNA was isolated from 
bacterial strains carrying the recombinant plasmids and, af-
ter specific treatment, was subjected to reverse transcription 
reaction using a specific reverse ‘SHORT’ primer complemen-
tary to the 3’ end of the strand encoding the particular syn-
thetic gene (Table 2). Obtained cDNAs were subsequently sub-
jected to amplification by the classical PCR technique using 
two ‘SHORT’ primer pairs (for/rev) homologous to each neu-
ropeptide sequence (Table 2). In result, DNA fragments were 
obtained which length corresponded to the length of individ-
ual synthetic genes confirming the presence of synthetic neu-
ropeptide gene transcripts (Figure 3).
Preliminary determination of optimal dose of L. lactis-
produced myelin peptides for oral tolerance induction
In first place, we concentrated our efforts on choosing the prop-
er dose of recombinant L. lactis bacteria, which would elicit the 
desired effect, which is a crucial step in obtaining tolerance. 
We applied two simple parameters: (i) mean score, which is 
widely used to reflect the physical condition of the animals 
and (ii) body mass of the animals, which allows assessing the 
general state of the animals (it is clear that the body mass 
of the animal with ongoing inflammatory process will drop).
To determine the optimal amount of myelin peptides for ef-
fective induction of oral tolerance, animals with evoked EAE 
(n=6) were fed for 20 consecutive days with whole-cell lysates 
of recombinant L. lactis producing MBP85-97, PLP139-151 and 
MOG35-55 fragments corresponding to doses 101–108 CFU 
consecutive days. Based on daily evaluation, the mean score of 
clinical symptoms and body mass index were counted (Figure 4A, 
4B). Development of the disease was initially scored during 
34 days post-infection (data not shown). First clinical symp-
toms appeared at 11 DPI. The relapse of EAE was observed be-
tween 11 and 14 DPI. After 14 DPI the remission of symptoms 
occurred. Therefore, the 11–14 DPI range was determined to 
give the most prominent differences in the mean scores for 
fed vs. non-fed EAE animals and used in further assays. Longer 
observation periods revealed spontaneous curing of animals.
Results obtained from this preliminary trial show influence of 
certain doses on EAE progression in rats. Feeding with bacteri-
al lysates corresponding to doses, 103, 105 and 106 CFU exhib-
ited the tendency to decrease the mean score, although this 
was not statistically relevant (Figure 4A). Significant (p<0.001) 
body mass reduction was observed in EAE rats in comparison 
to intact animals (NT) (Figure 4B). Application of bacterial prep-
arations showed a slight trend to increase the body mass of 
immunized animals, but this effect was statistically relevant 
(p<0.05) only in respect to dose 108 CFU. However, the same 
dose was ineffective in declining EAE progression. Thus, for 
further experiments two doses, 103 and 106 CFU, were select-
ed, which led at the same time to both, the decrease of mean 
score and increase of body mass vs. non-fed EAE animals.
Induction of oral tolerance by L. lactis-produced myelin 
peptides
To confirm that the chosen bacterial doses (103 and 106 CFU) 
are efficient in inhibiting the on-set of EAE, a subsequent ex-
periment was set-up on a larger animal group (n=12) using a 
20-day feeding scheme. Results confirmed our previous ob-
servations. Both doses (103, 106) did not only significantly de-
crease (p<0.05) clinical symptoms (Figure 5A), but also reduced 
body mass drop in fed vs. non-fed EAE animals (Figure 5B). To 
investigate whether the observed effect is caused by myelin 
peptide fragments and not by bacteria themselves, whole-cell 
lysates of L. lactis containing the empty plasmid (pIL253:PptcB) 
administered at the same doses (C 103, C 106) were used as 
control. No relevant differences in the mean score compared 
to non-fed EAE animals were observed (Figure 5A). In con-
trast, there was a statistically significant increase in the body 
mass index observed for animals fed with the control prepa-
ration at dose 106 CFU in comparison to non-fed EAE animals 
(Figure 5B). Still, the observed effect was lower than for my-
elin-producing bacteria.
To determine whether the applied feeding scheme is optimal, 
we further examined the effect of oral administration of whole-
cell lysates at 103 and 106 CFU/doses on EAE rats fed 4 times 
within one week. Such feeding scheme in combination with 
the applied doses was not sufficient in decreasing the clinical 
Figure 3.  Detection of synthetic myelin peptides gene expression 
in L. lactis by RT-PCR. (M) 100-bp DNA marker, (1) 
PLP139-151 gene transcript, (2) MOG35-55 gene 
transcript, (3) MBP85-97 gene transcript.
M 1 2 3
73 bp
54 bp48 bp
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symptoms in fed vs. non-fed EAE animals (Figure 6A). Body 
mass index was higher only for animals fed with preparations 
corresponding to 106 CFU/dose (Figure 6B). Also for this group a 
slight decrease of clinical symptoms was observed (Figure 6A).
We also did not note any dissimilarities in the mean score 
between fed and non-fed animals when lysates of L. lactis 
containing the empty plasmid were applied in 4-day feeding 
regimen (Figure 6A). Similarly as in the 20-fold feeding scheme, 
a substantial variation of body mass index was noted for ani-
mals fed with the control preparation at dose 106 CFU in com-
parison to non-fed EAE animals (Figure 6B).
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Figure 4.  Animals with EAE fed once per day for 
20 consecutive days with preparations 
containing mixed whole-cell lysates 
of recombinant L. lactis strains at 
doses 101–108 CFU (groups 101–108), 
producing MBP85-97, PLP139-151 
and MOG35-55 fragments. NT – 
non-treated animals, EAE – non-fed 
animals with EAE. (A) Mean score 
calculated at the peak of clinical 
symptoms [11–14 DPI]. n=6. (B) Body 
mass index at 14 DPI. Body mass at 
0 DPI considered as 1. n=6. * p<0.05; 
*** p<0.001.
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Figure 5.  Animals with EAE fed once per day for 
20 consecutive days with preparations 
containing mixed whole-cell lysates 
of recombinant L. lactis cells in doses 
103 or 106 CFU, containing the empty 
plasmid pIL253:PptcB (groups C 103 
and C 106) and producing MBP85-97, 
PLP139-151 and MOG35-55 fragments 
(groups 103 and 106). NT – non-treated 
animals, EAE – non-fed animals with 
EAE. (A) Mean score calculated at the 
peak of clinical symptoms [11–14 DPI]. 
n=12. * p<0.05. (B) Body mass index at 
14 DPI. Body mass at 0 DPI considered 
as 1. n=12. * p<0.05; ** p<0.01; 
*** p<0.001.
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Discussion
One of the alternative means of treating MS is induction of oral 
tolerance against natural myelin proteins, such as MBP, MOG, 
PLP, which according to the current knowledge are engaged in 
MS pathophysiology and its animal model – EAE [12–14]. Studies 
show that administration of specific myelin peptides or whole 
mammalian spinal cord hydrolysates (e.g., from pig, rat, mouse) 
prevents or partially inhibits EAE progression [15,16,18–21]. 
However, free antigen delivery for therapeutic purposes has 
several drawbacks, including laborious procedures in achieving 
adequate protein quantity and purity. Implementation in clinical 
therapy of novel, efficient immunomodulation strategies based 
on autoantigen presentation, in first place, aims at: (i) produc-
tion of sufficient amounts of autoantigens, and (ii) simple and 
stable delivery of antigens to mucosal surfaces. Taking this into 
account, various antigen-presenting systems have been devel-
oped, including antigen production in transgenic plants or an-
tigen administration enclosed in microsphere beads, fusion of 
antigens with mucosa-binding molecules (e.g., cholera toxin B 
subunit) and other [43–46]. Treatment of autoimmune diseas-
es by using live microbial vectors as antigen carriers has also 
been proven by multiple studies as a promising and effective 
approach for induction of specific tolerance [36,47,48].
Lactococcus lactis is a food-grade commensal bacterium, which 
due to its long and safe use in human and animal food produc-
tion has been assigned the GRAS (generally recognized as safe) 
status by the American Food and Drug Administration. Recent 
years have demonstrated that production of heterologous 
proteins in L. lactis cells for vaccine development is efficient 
and economically substantial [33,49–51]. A great advantage 
of using Lactococcus in medical applications is that it is non-
pathogenic and, as a Gram-positive bacteria, does not produce 
endotoxic lipopolysaccharides, and finally, does not induce in-
flammatory responses in healthy individuals.
Oral administration of L. lactis expressing antigens or allergens 
was previously shown to be proficient in induction of mucosal 
immune responses [52–54]. Moreover, L. lactis cells were deter-
mined to exhibit an adjuvant effect when administered as live 
antigen delivery vectors or a peptidoglycan matrix component 
[55,56]. These facts inclined us to investigate the potential ap-
plication of Lactococcus lactis bacteria as microbial factories for 
production and delivery of selected myelin peptide fragments 
to mucosal surface. Such approach could be especially useful in 
obtaining sufficient amounts of myelin proteins which normally 
are present at low levels, such as MOG, which constitutes only 
0.05% of myelin proteins of the central nervous system [57].
In this study we have synthetically generated genes encoding 
myelin epitopes of the mammalian central nervous system and 
cloned them in L. lactis cells to assess their potential application 
in specific induction of oral tolerance. To express myelin pep-
tide genes we used a pIL253-derived plasmid vector containing 
the L. lactis ptcB promoter. Our unpublished studies show that 
activity of the CcpA-controlled PptcB region, both plasmid- or 
chromosomally-located, is higher on cellobiose (activator) than 
on glucose due to catabolite repression [37,58, Aleksandrzak-
Piekarczyk – unpublished data]. Therefore, to ensure efficient 
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Figure 6.  Animals with EAE fed once per 
day for 4 days within a week with 
preparations containing mixed 
whole-cell lysates of recombinant 
L. lactis strains in doses 103 or 
106 CFU, containing the empty plasmid 
pIL253:PptcB (groups C 103 and C 106) 
and producing MBP85-97, PLP139-151 
and MOG35-55 fragments (groups 103 
and 106). NT – non-treated animals, 
EAE – non-fed animals with EAE. 
(A) Mean score calculated at the peak 
of clinical symptoms [11-14 DPI]. n=9. 
(B) Body mass index at 14 DPI. Body 
mass at 0 DPI considered as 1. n=9. 
* p<0.05; ** p<0.01; *** p<0.001.
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peptide production, cells were grown in medium with cellobiose. 
Based on two parameters, mean score and body mass, our re-
sults provide evidence that preparations of recombinant L. lac-
tis encoding myelin peptides grown on medium with cellobiose 
render a tolerogenic effect when administered orally to EAE rats.
In the study, EAE was evoked using guinea pig spinal cord ho-
mogenate, successfully used in previous studies [21]. By us-
ing the mixture of all myelin antigens, we imitate MS, where 
a broad spectrum of autoantigens is believed to be engaged 
in pathology. Application of an antigen mix containing three 
myelin epitopes was expected to more surely guarantee EAE 
suppression than a single antigen. Moreover, a mix of antigens 
resembles more closely the natural, physiological situation of 
tolerance induction in the gut. Our study shows that use of the 
microbially-expressed myelin epitopes, MOG35-55, PLP139-151, 
MBP85-97, induces oral tolerance in rats. Although, there is a 
limited number of works that examined the tolerogenic effect 
of peptide mixes, most recently Juryńczyk et al. [23] showed 
that transdermal application of a mix of the same peptides 
can be a promising approach in treatment of MS patients.
Among the crucial factors in obtaining the desired effect of oral 
tolerance are optimal antigen dose and feeding regimen. Our own 
previous experiments showed that administration of pig spinal 
cord hydrolysate based on a 4-day regimen during 1 week suc-
cessfully induced oral tolerance [21]. The second (20-day) scheme 
was implemented in experiments on recombinant lactobacilli pro-
ducing myelin proteins [47]. In this work we aimed at determin-
ing the most favorable feeding scheme for the designed lactococ-
cal recombinant cells. Results from conducted trials showed that 
feeding EAE animals according to a 20-day scheme with a mix-
ture of whole-cell lysates of L. lactis cells producing MBP85-97, 
PLP139-151 or MOG35-55, at 103 or 106 CFU/dose, is sufficient 
in reducing clinical symptoms and decreasing further body mass 
drop in fed vs. non-fed EAE animals. The fact that the same ef-
fect was obtained by applying these two concentrations could be 
explained by the dose-dependent mechanism of oral tolerance 
development, which occurs via clonal anergy or deletion (high 
doses), or active suppression (low doses) [11,59].
In contrast, the 4-fold feeding regimen did not reduce the clin-
ical symptoms of EAE. This may be owed to the necessity to 
precisely determine the dose of L. lactis administered to ani-
mals that would render the expected effect. Performing a pi-
lot test using a range of doses (101–108 CFU/dose), similar-
ly to the one made for the 20-day feeding scheme, might be 
useful in determining whether other bacterial doses than 103 
and 106 CFU are more efficient in the 4-time feeding proce-
dure. However, it seems that longer exposure of autoantigens 
in the gut resembles more the natural feeding scheme, im-
plied to be more advantageous than short-term feedings [60].
Another significant factor that should to be assessed is the 
time-scheme for antigen administration. Oral tolerance can be 
induced both, before or after disease induction, depending on 
the conditions of study (e.g., antigen dose and disease progres-
sion). Yet, numerous studies report that better suppression is 
observed when the antigen is delivered before immunization 
[61–64]. Feeding animals after immunization was reported to 
render limited suppression; yet, a prolonged feeding regimen 
was necessary [61,65]. Therefore, in our study animals were 
exposed to the recombinant antigen for 10 instead of 4 days 
before immunization and additionally for 10 days after immuni-
zation to assure better oral tolerance induction. Intragastric ad-
ministration of L. lactis containing the empty plasmid was also 
determined to influence the overall condition of EAE-induced 
rats. Although body mass gain/loss is not a direct parameter 
associated with oral tolerance, such effect could indicate the 
regulatory property of L. lactis bacteria. Literature data sug-
gests that Lactococcus could increase tolerogenic signals in-
duced by delivered autoantigens by influencing: (i) process-
ing or presentation of the antigen, and/or (ii) expression of 
co-stimulatory molecules on dendritic cells by affecting natu-
ral immune molecules [56]. In contrast, clinical symptoms in 
rats fed with control bacteria lysates were not as significant-
ly inhibited in comparison to rats fed with lysates of recombi-
nant bacteria encoding myelin epitopes, and only slightly lower 
than for non-fed EAE rats. This suggests that although L. lac-
tis cells alone can show some tolerogenic effect in the muco-
sa, myelin antigens are necessary in decreasing the clinical 
symptoms of EAE. The perspective of using L. lactis as a carri-
er may (only) play a boosting effect in evoking oral tolerance.
Conclusions
In summary, we synthetically generated genes encoding three 
selected myelin epitopes, which, cloned in L. lactis cells un-
der the lactococcal ptcB promoter, were demonstrated to ef-
ficiently induce oral tolerance by decreasing the clinical symp-
toms of EAE in rats. Moreover, the conducted animal studies 
deliver valuable information concerning the optimal adminis-
tration scheme for L. lactis-produced myelin antigens. Further 
studies on optimizing the dose and feeding regimen as well 
as peptide expression and delivery will be needed to deter-
mine whether increase of the therapeutic effect of L. lactis 
preparations could be obtained. Nonetheless, application of 
Lactococcus bacteria, which have a documented safe effect on 
human and animal health, for production of mammalian my-
elin epitopes and oral administration to induce immunotoler-
ance seems to be an attractive means of treatment of auto-
immune diseases. Data obtained in this work creates further 
perspectives for seeking new therapies for multiple sclerosis 
via the oral tolerance phenomenon.
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